Page last updated: 2024-11-08

temocapril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID443874
CHEMBL ID2110627
CHEBI ID135771
SCHEMBL ID188165
MeSH IDM0156456

Synonyms (33)

Synonym
1,4-thiazepine-4(5h)-acetic acid, 6-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, (2s-(2alpha,6beta(r*)))-
cs622
temocaprilum [inn-latin]
temocapril
temocapril [inn:ban]
(2s-(2alpha,6beta(r*)))-6-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5h)-acetic acid
CHEBI:135771
temocapril (inn)
D08566
111902-57-9
2-[(2s,6r)-6-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid
temocaprilum
18iz008eu6 ,
unii-18iz008eu6
CHEMBL2110627
S2100
temocapril [inn]
(+)-(2s,6r)-6-(((1s)-1-carboxy-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5h)-acetic acid, 6-ethyl ester
temocapril [who-dd]
temocapril [mi]
DB08836
SCHEMBL188165
DTXSID3048239
2-((2s,6r)-6-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl)acetic acid
AB01566891_01
2-((2s,6r)-6-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl)acetic acid
Q7698194
gtpl11736
2-((2s,6r)-6-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl)aceticacid
NCGC00263583-02
discontinued see t017301
CS-0020063
HY-100713

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Although the participation of the particular transporters in observed drug-drug interactions can be difficult to confirm in humans, this review focuses mainly on pharmacokinetic interactions of clinically important drugs."( Transporter-mediated Drug Interactions.
Tsuji, A, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Temocapril Metabolism Pathway02
Temocapril Action Pathway34

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency23.91850.01237.983543.2770AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
cholesterol biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
response to toxic substanceLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxLiver carboxylesterase 1Homo sapiens (human)
negative regulation of cholesterol storageLiver carboxylesterase 1Homo sapiens (human)
epithelial cell differentiationLiver carboxylesterase 1Homo sapiens (human)
cholesterol homeostasisLiver carboxylesterase 1Homo sapiens (human)
reverse cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
medium-chain fatty acid metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to cholesterolLiver carboxylesterase 1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusLiver carboxylesterase 1Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid secretionLiver carboxylesterase 1Homo sapiens (human)
lipid catabolic processLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
sterol esterase activityLiver carboxylesterase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylesterase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
cytoplasmLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulum lumenLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
cytosolLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID1222124Drug hydrolysis in intact Wistar rat jejunal S9 fraction at 500 uM assessed per mg protein in presence of 1000 uM CES inhibitor BNPP2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222112Drug uptake in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP assessed as rate of temocaprilat disappearance at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222101Drug hydrolysis in Wistar rat duodenal S9 fraction in presence of 1 mM CES inhibitor BNPP2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222111Intracellular drug level in Wistar rat jejunum assessed as temocaprilat level pre-perfused with 400 uM CES inhibitor BNPP at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222128Drug hydrolysis in perfused Wistar rat jejunal S9 fraction at 500 uM assessed per mg protein in presence of 400 uM CES inhibitor BNPP2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222104Drug uptake in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP assessed as rate of drug appearance at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222154Ratio of Vmax to Km for drug jejunal in Wistar rat duodenal S9 fraction assessed per mg protein2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222120Drug hydrolysis in intact Wistar rat jejunum mucosal homogenate at 500 uM assessed per mg protein in presence of 100 uM CES inhibitor BNPP2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222135Apparent absorption clearance in Wistar rat jejunum at 100 uM at pH 7.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222139Intracellular drug level in Wistar rat jejunum at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222113Drug uptake in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP assessed as rate of temocaprilat appearance at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222149Drug hydrolysis in Wistar rat duodenal S9 fraction2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222106Drug uptake in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP assessed as rate of temocaprilat appearance at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222156Drug uptake in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP assessed as rate of drug disappearance at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222141Intracellular drug level in Wistar rat jejunum treated with Temocaprilat at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222105Drug uptake in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP assessed as rate of temocaprilat disappearance at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222132Apparent hydrolytic clearance in Wistar rat jejunum at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222127Drug hydrolysis in perfused Wistar rat jejunal S9 fraction at 500 uM assessed per mg protein2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222116Apparent absorption clearance in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222150Drug hydrolysis in Wistar rat jejunal S9 fraction2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222126Drug hydrolysis in perfused Wistar rat jejunum mucosal homogenate at 500 uM assessed per mg protein in presence of 400 uM CES inhibitor BNPP2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID456232Activity at human recombinant CES1 expressed in baculovirus-infected Spodoptera frugiperda Sf21 cells assessed as substrate hydrolysis by fluorescence assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations.
AID1222122Drug hydrolysis in intact Wistar rat jejunal S9 fraction at 500 uM assessed per mg protein2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222130Permeability in Wistar rat jejunum at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222121Drug hydrolysis in intact Wistar rat jejunum mucosal homogenate at 500 uM assessed per mg protein in presence of 1000 uM CES inhibitor BNPP2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222140Intracellular drug level in Wistar rat jejunum at 100 uM at pH 7.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222102Drug hydrolysis in Wistar rat jejunal S9 fraction in presence of 1 mM CES inhibitor BNPP2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID1222108Apparent hydrolytic clearance in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID681152TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:4
Transporter-mediated Drug Interactions.
AID1222129Partition coefficient, log P between n-octanol and phosphate buffer at pH 7.42011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222118Intracellular drug level in Wistar rat jejunum assessed as temocaprilat level pre-perfused with 400 uM CES inhibitor BNPP at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222137Apparent absorption clearance in Wistar rat jejunum at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID679582TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 uM, Temocapril: 50 uM) in MDR1-expressing LLC-PK1 cells2002Life sciences, Feb-15, Volume: 70, Issue:13
Interaction of digoxin with antihypertensive drugs via MDR1.
AID1222125Drug hydrolysis in perfused Wistar rat jejunum mucosal homogenate at 500 uM assessed per mg protein2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222134Permeability in Wistar rat jejunum at 100 uM at pH 7.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222115Apparent hydrolytic clearance in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222114Permeability in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222157Permeability in Wistar rat jejunum at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222131Apparent hydrolytic clearance in Wistar rat jejunum at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222123Drug hydrolysis in intact Wistar rat jejunal S9 fraction at 500 uM assessed per mg protein in presence of 100 uM CES inhibitor BNPP2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222146Drug uptake in Wistar rat jejunum mesenteric vein assessed as rate of drug appearance at 100 uM by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222155Drug uptake in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP assessed as rate of drug disappearance at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222142Intracellular drug level in Wistar rat jejunum treated with Temocaprilat at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222143Intracellular drug level in Wistar rat jejunum treated with Temocaprilat at 100 uM at pH 7.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222119Drug hydrolysis in intact Wistar rat jejunum mucosal homogenate at 500 uM assessed per mg protein2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222145Drug degradation in Wistar rat jejunum lumen assessed as rate of drug disappearance at 100 uM by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222133Apparent absorption clearance in Wistar rat jejunum at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222153Ratio of Vmax to Km for drug hydrolysis in Wistar rat duodenal S9 fraction assessed per mg protein2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222107Permeability in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222109Apparent absorption clearance in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222117Intracellular drug level in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222138Intracellular drug level in Wistar rat jejunum at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222151Drug hydrolysis in Wistar rat duodenal S9 fraction assessed as rate of hydrolysis per mg protein2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222136Apparent hydrolytic clearance in Wistar rat jejunum at 100 uM at pH 7.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222152Drug hydrolysis in Wistar rat jejunal S9 fraction assessed as rate of hydrolysis per mg protein2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222103Drug uptake in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP assessed as rate of drug appearance at 100 uM at pH 6.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
AID1222110Intracellular drug level in Wistar rat jejunum pre-perfused with 400 uM CES inhibitor BNPP at 100 uM at pH 5.4 by in-situ single-pass perfusion method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.48 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index32.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]